Piv­otal myas­the­nia gravis da­ta from ar­genx au­gur well for FcRn in­hibitors in de­vel­op­ment

Lead­ing the pack of biotechs vy­ing for a piece of the gen­er­al­ized myas­the­nia gravis (gMG) mar­ket with an FcRn in­hibitor, ar­genx on Tues­day un­veiled keen­ly an­tic­i­pat­ed pos­i­tive late-stage da­ta on its lead as­set, bring­ing it one step clos­er to reg­u­la­to­ry ap­proval and lift­ing its stock by more than a third.

De­spite steroids, im­muno­sup­pres­sants, acetyl­cholinesterase in­hibitors, and Alex­ion’s Soliris, pa­tients with the rare, chron­ic neu­ro­mus­cu­lar dis­or­der (more than 100,000 in the Unit­ed States and Eu­rope) don’t nec­es­sar­i­ly ben­e­fit from these ex­ist­ing op­tions, leav­ing room for the crop of FcRn in­hibitors in de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.